CIP
ONCE

Chartwell Investment Partners’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Chartwell Investment Partners’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-19,822
Closed -$1.02M – 438
2017
Q4 		$1.02M Sell
19,822
-1,349
-6% -$96.9K 0.03% 383
2017
Q3 		$1.89M Buy
+21,171
New +$1.61M 0.06% 330

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Chartwell Investment Partners's ONCE Position: Q1 2018 in Review

Chartwell Investment Partners sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2018, closing a stake of 19,822 shares — an estimated $1.02M sold.

Chartwell Investment Partners first reported a position in ONCE in Q3 2017 and held it in 2 quarters. The position peaked at $1.89M in Q3 2017. 162 funds tracked by Wall St. Rank hold ONCE as of Q1 2018.

  • Chartwell Investment Partners reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Chartwell Investment Partners sold 19,822 Spark Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $1.02M.
  • Chartwell Investment Partners first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Chartwell Investment Partners's Spark Therapeutics, Inc. Common Stock position peaked at $1.89M in Q3 2017.
  • 162 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Chartwell Investment Partners's 13F filing for Q1 2018, filed 8 May 2018.